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ABSTRACT
The c-Myc transcription factor regulates a wide set of
genes involved in processes such as proliferation,
differentiation and apoptosis. Therefore, altered
expression of Myc leads to deregulation of a large
number of target genes and, as a consequence, to
tumorigenesis. For understanding Myc-induced
transformation, identification of these target genes
is essential. In this study, we searched for Myc target
genes involved in lymphomagenesis using different
mouse T and B cell lymphoma cell lines transformed
by a conditional Myc-allele. Target genes obtained
by microarray experiments were further subjected
to a kinetic analysis of mRNA expression upon Myc
inactivation/reactivation, bioinformatic examination
of Myc binding sites and chromatin immunoprecipi-
tation. This approach allowed us to define targets
whose activation is a direct consequence of Myc bind-
ing. Among the 38 novel Myc targets, we identified
several genes implicated in the tumor development.
These genes are not only relevant for mouse lympho-
mas because we observed their upregulation in
human lymphomas as well. Our findings further the
understanding of Myc-induced lymphomagenesis
and help toward developing more efficient antitumor
strategies.
INTRODUCTION
The c-Myc (Myc) proto-oncogene belongs to a family of
related proteins that also include N-Myc, L-Myc, B-Myc
and s-Myc (1); however, only c-Myc, N-Myc and L-Myc
possess neoplastic potential (2,3). Under physiological condi-
tions, Myc is broadly expressed during embryogenesis, as well
as in adult tissues with high proliferative capacity. A null
mutation in the Myc gene causes lethality at day 10.5 of
gestation, which suggests that, it is critical for early develop-
ment (4). Generally, Myc expression correlates closely with
the proliferation status of a cell: in quiescent cells, Myc is
almost undetectable whereas, upon mitogen stimulation,
mRNA and protein levels are rapidly induced (3). Cell
cycle, differentiation, apoptosis, metabolism, cell adhesion,
and hematopoietic homeostasis are key processes that are
regulated by Myc (5–9). Altered expression of Myc was
found in a wide variety of human and animal tumors including
breast carcinomas, colon carcinomas, cervical carcinomas,
small cell lung carcinomas, osteosarcomas, glioblastomas,
myeloid leukemias, and lymphomas (10).
The Myc proto-oncogene encodes a transcription factor
with a C-terminal basic-helix–loop–helix/leucine zipper
(bHLHZ) domain that promotes DNA and protein–protein
interactions (11–13). For its function, Myc needs to dimerize
with a related bHLH protein named Max. Myc–Max hetero-
dimers are capable of binding specific DNA sequences, called
the E-boxes (14,15). Dimerization with Max and binding to the
E-box are essential for Myc to promote gene expression. Max
homodimers compete with Myc–Max heterodimers for bind-
ing to DNA target sites (16). Mutations in the N-terminal Myc
transactivation domain lead to abrogation of Myc activity
(17–19). In addition to activation of a large set of genes,
Myc has also been shown to repress some genes. The mechan-
ism of Myc repression of target genes is not well understood.
Possibly, this repression occurs via interference with transcrip-
tion factors that is required for gene activation (20,21). In addi-
tion, Myc is recruited to core promoters through protein–protein
interactions with TFII-I, YY-1, Sp-1 and Miz-1(22). Finally,
interactions of Myc with Smad-2 and -3 and NF-Y proteins may
contribute to repression of individual promoters (22).
Different approaches toward identification of the Myc target
genes have been reported over the last few years (23–30). In
essence, they are based on identification of genes that are
differentially expressed, as a result of enforced Myc expres-
sion or on analysis of regulatory elements of genes that contain
Myc–Max consensus binding sites. Since Myc plays such a
critical role in a wide variety of physiological and pathophy-
siological processes, different model systems have been used
to investigate target genes. Only a portion of the described
genes overlapped in the separate studies. In addition, a huge
number of genes that are not dependent on Myc change its
expression as a consequence of Myc-induced cell growth and
proliferation, differentiation or apoptosis, thus leading to the
isolation of indirect targets.
We recently established a transgenic mouse model in which
Myc is conditionally expressed in lymphoid cells using the
tetracycline-controlled system of gene regulation (31). In these
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mice, the tetracycline-transactivator (tTA) is under the control
of the intronic Ig-m heavy chain enhancer (mE) and a minimal
promoter, and is specifically expressed in lymphocytes. This
transactivator then activates the transcription of a second
transgene cassette consisting of a Myc proto-oncogene and
a luciferase reporter gene. In the presence of doxycycline,
the expression of both Myc and luciferase are aborted. Double
transgenic mice (tTA/Myc mice) develop lymphomas that
regress upon doxycycline administration (31).
Different cell lines were established from lymphoma-
bearing mice. Further characterization by fluorescence
activated cell sorting (FACS) showed expression of cell
surface markers that were characteristic for T or B cells. In
addition, fluorescence in situ hybridization (FISH) analyses
revealed that T cell lines could be divided in two subgroups:
one containing two copies of chromosome 15 and one with a
chromosome 15 trisomy. Doxycycline treatment aborts
expression of transgenic Myc mRNA in lymphoma cell
lines within 2–8 h. As a consequence, 24–48 h later, the
cells change their morphology, stop proliferation and begin
to show early signs of apoptosis (31).
Using this system, we aimed at identifying genes commonly
expressed in different subtypes of Myc-induced lymphomas.
In a step-by-step analysis under stringent conditions, by the
use of microarray hybridization, kinetic experiments,
bioinformatic analysis and chromatin immunoprecipitation,
we were able to identify several novel direct Myc targets
with a potential role in lymphomagenesis.
MATERIALS AND METHODS
Cells and culture conditions
The cell lines used in this study were derived from mouse T or
B cell lymphomas bearing a conditional human c-Myc allele
(31). Two B cell lines, 5522 B and 5532 B and four T cell lines,
4502 T, 1415 T, 4347 T and 7755 T, were used in the Gene
Chip experiment. FISH analysis had revealed that T cell lines
4347 T and 7755 T have a trisomy of chromosome 15. An
additional set of two B (5542 B and 5527 B) and four T cell
lines (4702 T, 377 T, 1749 T and 4491 T) were used to confirm
results obtained by microarray hybridization. All the cell lines
were established and characterized as described previously
(31). The cells were cultured in RPMI 1640 supplemented
with 10% fetal calf serum(FCS), penicillin/streptomycin,
non-essential amino acids, glutamine and beta-mercaptoetha-
nol (all from PAN Biotech, Germany).
To suppress the expression of Myc oncogene, the cells were
treated with 2 mg/ml of doxycycline (ICN Biomedicals Inc.,
OH) for 12 h. For kinetic experiments, the cells were pre-
treated with doxycycline for 12 h, extensively washed, and
further incubated in cell culture medium without doxycycline
for the indicated time intervals.
Human primary B cells were isolated from buffy coats of
three healthy donors using B Cell Isolation Kit II (Miltenyi
Biotec, Germany) according to the manufacturer’s instruction.
Three sporadic European Burkitt lymphomas were included
[for details see case number 1, 4 and 6; (32)]. Diagnosis was
based on morphology, immunohistology and molecular cyto-
genetics. All three lymphomas had a diffuse growth pattern of
cohesive small to medium sized cells and the typical starry sky
pattern. The immunoprofile was: CD20+ (3/3); CD10 (3/3);
CD38+ (2/3); CD77 (3/3); IgM+ (3/3); MHC Class I+ (3/3)
and MHC Class II+ (3/3); Bcl2 (2/3); CD23 (3/3). The
proliferation index was assessed by Ki-67 staining and was
above 90% in all lymphomas. EBV virus was not detected by
Western blotting. FISH revealed a Myc rearrangement with a
diagnostic signal constellation for the translocation t(8;14) in 2
lymphomas, whereas one lymphoma showed a signal pattern
that indicates a breakpoint in the Myc locus with an elusive
translocation partner.
Microarray analysis
About 2 · 107 cells were cultured in the presence or absence of
doxycycline for 12 h, and RNA was analyzed by Affymetrix
expression profiling using the Murine Array Gene Chip
U74Av2.
Results obtained by scanning hybridized microarrays were
further analyzed using Affymetrix Microarray Suite software
Version 5.0.0.032 (Affymetrix Inc., CA) and NETAFFX
Analysis Center Tools (Affymetrix Inc.). Quality control
and normalization of results were performed using standard
Affymetrix test genes and b-actin and GAPDH as housekeep-
ing controls.
All raw data are made MIAME (‘Minimal Information
About a Microarray Experiment’) compliant and submitted
to ArrayExpress database (www.ebi.ac.uk/arrayexpress/)
with an accession number E-MEXP-169.
Analysis of mRNA expression levels
Total RNA was isolated from cells using High Pure RNA
Isolation Kit (Roche, Switzerland) and reverse transcribed
using M-MLV Reverse Transcriptase (Invitrogen, CA) with
random hexamer primers (Roche). The cDNAs were subjected
to PCR using Taq Polymerase (Pharmacia, UK) and primers
specific for indicated genes. As a housekeeping control we
used primers specific for b-actin. All primer sequences are
available upon request.
Proliferation assay
The cells were incubated for 12 h in the presence or absence of
doxycycline. Afterwards, the cells were extensively washed,
resuspended in RPMI and stained for 5 min with carboxy-
fluorescein diacetate succinimidyl ester (CFSE) (Molecular
Probes, OR) at a final concentration of 2 mM. One aliquot
of both treated and untreated cells was used for FACS analysis
and the rest was replated in cell culture medium and analyzed
after different time periods. Control samples of cells continu-
ously treated with doxycycline were included. Reduction of
CFSE fluorescence as a measure of proliferation was moni-
tored at the indicated time points using FACSCalibur and
CellQuest software (BD, CA).
Western blot
The cell lysates were prepared using a buffer containing
20 mM HEPES pH 7.9, 0.42 M NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 25% Glycerol, 1 mM DTT and 1 mM PMSF.
The proteins were separated on 12.5% SDS–polyacrylamide
gel and blotted on Immobilion-P transfer membrane
(Millipore, MA). Membrane blocking and incubation with
antibodies involved standard procedures. Immunoblots were
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probed with rabbit polyclonal c-Myc (N-262) and anti-RelA
(both from Santa Cruz, CA). As a secondary antibody we used
donkey anti-rabbit-HRP IgG (Jackson Immunoresearch, PA).
Proteins were visualized using ECL detection kit (Amersham,
UK).
Apoptosis assay
The apoptosis was assayed using the Annexin V-FITC Apop-
tosis Detection Kit obtained from Pharmingen. Annexin V and
PI staining were performed according to the manufacturer’s
instructions.
Bioinformatic methods
Mouse genomic DNA sequences obtained from Celera
Discovery System were searched for CACGTG motifs located
within a distance of 2 kb on either side of the transcription start
site. Preferentially, E-boxes situated in the first intron within
CpG islands were chosen for further ChIP analysis.
Chromatin immunoprecipitation (ChIP) assay
About 2 · 107 cells were incubated for 12 h in the presence or
absence of doxycycline, fixed in 1% formaldehyde, and chro-
matin was precipitated using a ChIP Assay Kit (Upstate, NY)
following the instructions of the manufacturer. Rabbit poly-
clonal antibodies specific for c-Myc (N-262), Lyn, and PLCg
(all from Santa Cruz, CA), acetyl-histone H3, and acetyl-
histone H4 (both from Upstate, NY) were used to precipitate
chromatin. The primers used for amplification of genomic
sequences containing Myc binding site for Ifrd2 were:
50-ggg ggt gtt ccg tga ttc c-30 and 50-acg ctc ttt ctg gtg tgg
ttt-30; Pa2g4: 50-cga aaa gga agc ggc cag ct-30 and 5-ccc cac taa
gaa gac ctg aag-30; Picalm (phosphatidylinositol-binding cla-
thrin assembly protein also annotated as clathrin assembly
lymphoid-myeloid leukemia gene): 50-cgg ctc gga tgc gtg
ttc aa-30 and 50-ttg cct gcc gac tgc cta ac-30; Clpp: 50-gga
cga gca gga agt agc ca-30 and 50-tgt gtc gta gat ggc cag
gc-30; Timm10: 50-tct gct gag agc ctg gaa ct-30 and 50-cca
agt acc cct caa aca agc-30; Lap3: 50-gca cag gtc cgg ctt tcc
aa-30 and 50-cca gag acc tct cac tcc ca-30.
RESULTS
Screening for Myc targets using microarray analysis
During the analysis of cell lines derived from tTA/Myc mice
with advanced lymphomas (31), we observed that doxycycline
treatment for 12 h, completely abolished expression of the
transgenic Myc protein (Figure 1A). Yet cells still did not
show obvious signs of apoptosis, i.e. Annexin V binding
(Figure 1B). In addition, after such a 12 h treatment cell
proliferation could be reactivated by washing out doxycycline
(see below). Therefore, we decided to use these conditions to
study the regulation of Myc target genes.
Three subtypes of lymphomas were used for microarray
hybridization experiment: B cell lymphomas, T cell lympho-
mas that were diploid for chromosome 15 (T cell lymphoma
2· chromosome 15) and T cell lymphomas with trisomy of
chromosome 15 (T cell lymphoma 3· chromosome 15). For
each lymphoma subtype two cell lines were chosen, cultured
to reach log phase of growth and then 2 · 107 cells were either
treated or not treated with 2 mg/ml of doxycycline for 12 h to
shut off Myc expression. Gene expression profiles of these
two conditions were then compared by Affymetrix Murine
Genome Array U74Av2 gene chip that contain about
12 000 sequences. All raw data are made MIAME (‘Minimal
Information About a Microarray Experiment’) compliant
and submitted to ArrayExpress database (www.ebi.ac.uk/
arrayexpress/) with an accession number E-MEXP-169.
Our approach was to reduce the prevalence of non-specific
genes and look for common events in Myc-induced lympho-
magenesis by comparing the expression patterns of different
lymphoma subtypes. As a first step, we compared mRNA
expression of each of the six doxycycline-treated lines to
the corresponding non-treated sample. Genes whose expres-
sion was increased by doxycycline treatment were considered
as downregulated by Myc, whereas genes with decreased
expression were considered as upregulated by Myc. We
applied a threshold of a 2-fold change in expression levels
between doxycycline treated and non-treated cells. Further,
lists of upregulated and downregulated genes for each cell
line from the same lymphoma subtypes were compared and
only genes altered in both lines were considered as common
for the certain lymphoma subtype (Figure 2). To obtain lists of
Figure 1. Expression of transgenic Myc is regulated by doxycycline treatment.
Cell lines were incubated for 12 h in the presence or absence of doxycycline
(2mg/ml). Afterwards, cells were harvested, lysed in Dignam C buffer and 50mg
of the protein was analyzed by western blotting. After detection of Myc the
membrane was stripped and reprobed with a rabbit polyclonal anti-RelA
antibody as loading control. Representative examples of the transgenic Myc
expression in B and T cell lines are shown (A). An aliquot of cells was used to
test apoptosis by Annexin V staining (B).
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genes that were commonly up- or downregulated in all
analyzed lymphoma lines, lists of genes that were altered in
each subtype were matched. Thus, as a final result, we
obtained lists of genes up- or downregulated more than
2-fold in all six samples (ranging up to 27-fold of regulation).
The list of commonly upregulated genes contains 88 genes
(Figure 2A and Table 1), whereas only one gene was consis-
tently downregulated in all cell lines (Figure 2B and Table 1).
Out of the 88 genes upregulated by Myc, 61 were described as
genes with known protein function, whereas 27 were not anno-
tated sequences (Table 1). The list of the upregulated genes
that we obtained, showed substantial overlaps with the Myc
target genes database published on the website (www.myc-
cancergene.org) However, we observed the regulation of 37
additional genes that, to the best of our knowledge, had
not been described previously as Myc targets (Table 1). To
further analyze Myc target genes observed in this study, we
first classified them according to their biological function
(Table 1). As expected (1,33), the majority of genes regulated
by Myc is involved in processes such as cell proliferation,
differentiation, and signaling, or reflected increased require-
ments of highly proliferative cells for protein synthesis,
modification, and metabolism.
Confirmation of Gene Chip data
To further confirm the results obtained by Gene Chip analysis,
RT–PCR was performed using RNA isolated from cells that
were identically treated as for the microarray hybridization.
Several genes were chosen from the list of common upregu-
lated Myc targets: Ifrd2, Pa2g4, Picalm, Timm10, Lap3, Sms
and Gsto1. In agreement with the Gene Chip data, doxycycline
treatment decreased mRNA levels for these genes in all tested
lines (Figure 3A). In addition, expression of Itgam, the only
gene commonly downregulated by Myc, was indeed increased
in the presence of doxycycline (Figure 3A).
Myc target genes that were identified by Gene Chip analysis
and additionally confirmed by RT–PCR were further evaluated
using a supplementary set of two B and four T cell lines, as
biological replicates, to analyze the pattern of expression of
these genes in the presence or absence of Myc. In all cases,
results obtained from additional cell lines corresponded to the
results from Gene Chip analysis and RT–PCR obtained on the
first set of six cell lines (Figure 3B). Therefore, the specific
regulation of those target genes by Myc was not only true for
the cell lines chosen for Gene Chip analysis, but also for the
additional set of six other lymphomas.
We also tested the mRNA expression levels of several
genes, which, according to the approach we used, appeared
to be specifically regulated by Myc in B or T cell lymphomas.
We chose Amd1 and CD2 as examples for up- and down-
regulated genes specific for B cell lymphoma and Thop1
and CD28 as examples for T cell lymphoma specific genes.
Amd1 was indeed downregulated and CD2 was upregulated in
the presence of doxycycline in both B cell lines (Figure 3C).
Similarly, the expression of Thop1 in all T cell lines was
clearly reduced in the absence of Myc while CD28 expression
was enhanced under the same conditions (Figure 3D).
Target gene expression follows the kinetics of Myc
mRNA expression
Myc in combination with Max directly induces transcription of
various genes (16). However, not only are direct targets acti-
vated by Myc expression but Myc regulated genes may also
control the expression of a second wave of target genes. A
prediction for direct target genes is that their expression should
follow the kinetics of Myc expression. We treated cells with
2mg/ml of doxycycline for 12 h to suppress Myc expression
and then later, an aliquot of cells was used to isolate RNA. The
rest of the cells were intensively washed and replated in a
medium without doxycycline. In order to follow the reexpres-
sion of Myc and potential reexpression of Myc target genes,
cells were sampled at different time points (2,4,8 and 24 h) and
RNA was isolated. We found that cells treated with doxycy-
cline are capable of reestablishling the expression of Myc
mRNA within 8 h of doxycycline withdrawal (Figure 4A).
To avoid the possibility that the reappearance of Myc after
8 h might reflect differences due to advanced proliferation of
Myc-expressing cells, which perhaps did not respond to doxy-
cycline treatment, we simultaneously followed cell prolifera-
tion, using staining with vital dye CFSE, immediately after
doxycycline removal. As a control, cells that were not treated
with doxycycline were used. No significant reduction of CFSE
fluorescence was observed at the time point of 8 h in neither
control nor doxycyline-treated cells (Figure 4B). This indi-
cates that increased levels of Myc mRNA are indeed due to
reactivation of transgenic construct and not just a consequence
of overgrowth of cells that perhaps did not respond to doxy-
cycline treatment. Interestingly, whereas all control cells
divided at least once upon doxycycline withdrawal after 48 h,
cells that were continuously treated did not proliferate at all
and cells that were pretreated for 12 h showed a certain level of
heterogeneity. Reexpression of transgenic Myc was sufficient
to reactivate dormitory cells; however, a percentage of cells
probably underwent a permanent arrest of growth and these
cells did not proliferate upon doxycycline removal (Figure 4B).
Figure 2. Myc regulates the expression of a large set of genes. Cell lines were
divided into three subgroups: B cell lymphomas (cell lines 5522 B and 5532 B),
T cell lymphomas with 2· chromosome 15 (4502 T and 1415 T) and T cell
lymphomas with 3· chromosome 15 (4347 T and 7755 T). For the hybridization
to Gene Chip Murine Genome Array U74Av2 cell lines were treated for 12 h
with 2 mg/ml of doxycycline. Expression patterns for each treated line were
compared with untreated control and genes that were up- and downregulated by
Myc were further analyzed. Venn diagrams present numbers of genes altered in
each of three subgroups of lymphomas. Numbers in each subgroup represents
genes altered in both cell lines. (A) The 88 genes upregulated by Myc are
common for all three subgroups of lymphomas. (B) Only one gene was
found to be downregulated in all lymphoma subgroups.
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It is not clear at present whether Myc expression was reacti-
vated in this cell population.
The majority of analyzed genes showed the same expression
pattern as Myc. After 12 h of doxycycline treatment, transcrip-
tion of all genes that were positively regulated by Myc was
decreased (Figure 4A). In contrast, transcription of Itgam,
barely detectable in the control cells, significantly increased
upon Myc inactivation (Figure 4A). Reappearance of Myc
after 8 h led to an increase of mRNA levels of Pa2g4, Picalm,
Timm10, Lap3, Gsto1 and Sod2, whereas transcription of
Itgam decreased (Figure 4A). In contrast, the Myc effects
on some target genes might be indirect. Umps was reexpressed
after 24 h and mRNA level for Hells did not increase even
during this time period (Figure 4A).
Myc binds to regulatory regions of direct target genes
An important mechanism by which Myc induces activation of
direct target genes is by dimerization with Max and direct
binding to the E-box (CANNTG) DNA sequence, mostly
CACGTG (11,34,35). To identify direct targets of Myc, we
used bioinformatics tools as a preselection method and con-
tinued further with experimental analysis of Myc binding to
the CACGTG-containing sequence, using ChIP. We searched
the mouse genomic DNA sequences of our putative target
Table 1. Myc regulates different sets of genes
Genes upregulated by Myc
Metabolism
Phosphoribosylglycinamide formyltransferase (Gart)a
Inosine 50-phosphate dehydrogenase 2 (Impdh2)a
Phosphofructokinase, liver, B-type (Pfk1)
Expressed in non-metastatic cells 1, protein (Nme1)a
Hexokinase 2 (Hk2)a
ATPase, H+ transporting, V1 subunit F (Atp6v1f)
Phosphoserine aminotransferase 1 (Psat1)
Spermine synthase (Sms)
Serine hydroxymethyl transferase 1 (soluble) (Shmt1)a
Triosephosphate isomerase (Tpi)
Protein biosynthesis and modification
DnaJ (Hsp40) homolog, subfamily C, member 2 (Dnajc2)
Chaperonin subunit 6a (zeta) (Cct6a)a
FK506 binding protein 4 (Fkbp4)a
Importin 4 (Ipo4)
RRS1 ribosome biogenesis regulator homolog (S.cerevisiae) (Rrs1)a
Peptidylprolyl isomerase F (cyclophilin F) (Ppif)a
Nucleolin (Ncl)a
Cell cycling
Block of proliferation 1 (Bop1)a
CD40 ligand-activated specific transcript 3 (Clast3-pending)
Chromosome condensation 1 (Chc1)a
Pericentrin 2 (Pcnt2)
Peter pan homolog (Drosophila) (Ppan)
Cell differentiation
Interferon-related developmental regulator 2 (Ifrd2)a
Helicase, lymphoid specific (Hells)
DNA maintenance and repair
Checkpoint kinase 1 homolog (S.pombe) (Chek1)
Polymerase (DNA directed), delta 2, regulatory subunit (Pold2)a
Stress response
Stress-induced phosphoprotein 1 (Stip1)
Superoxide dismutase 2, mitochondrial (Sod2)
Glutathione S-transferase omega 1 (Gsto1)
Translation
Proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 (Psmd7)a
Nuclear proteins
Mki67 (FHA domain) interacting nucleolar phosphoprotein (Mki67ip)
Nucleolar and coiled-body phosphoprotein 1 (Nolc1)a
EBNA1 binding protein 2 (Ebna1bp2)a
Nucleosome assembly protein 1-like 1 (Nap1l1)a
Proteolysis and peptidolysis
Proliferation-associated 2G4 (Pa2g4)a
Insulin degrading enzyme (Ide)
Leucine aminopeptidase 3 (Lap3)
Caseinolytic protease, ATP-dependent, proteolytic subunit homolog
(E.coli) (Clpp)
Mitochondrial proteins
Translocase of outer mitochondrial membrane 40 homolog (yeast)
(Tomm40)
Translocase of inner mitochondrial membrane 10 homolog (yeast)
(Timm10)
A kinase (PRKA) anchor protein 1 (Akap1)a
Transcription
Transcription elongation regulator 1 (CA150) (Tcerg1)
Transcription factor Dp 1 (Tfdp1)a
General control of amino acid synthesis-like 2 (yeast) (Gcn512)
Coactivator-associated arginine methyltransferase 1 (Carm1-pending)
Signaling
Thyroid hormone receptor interactor 13 (Trip13)a
RAN binding protein 1 (Ranbp1)a
Phosphatidylinositol binding clathrin assembly protein (Picalm)
Glucosidase 1 (Gcs1)a
Other
SET and MYND domain containing 5 (Smyd5)
Glutamate rich WD repeat protein GRWD (Grwd-pending)
G7e protein (G7e-pending)
Similar to KIAA0595 protein (LOC226169)
Expressed sequence AA408582 (AA408582)
Carnitine deficiency-associated gene expressed in ventricle 3 (Cdv3)
Table 1. Continued
HIV-1 Rev binding protein 2 (Hrb2)
SET and MYND domain containing 2 (Smyd2)
NS1-associated protein 1-like (Nsap 1l-pending)
Fibroblast growth factor inducible 15 (Fin15)
Mus musculus goliath-related E3 ubiquitin ligase 4 (Greul4)
Myosin Va (Myo5a)
Not annotated sequences
RIKEN cDNA 2410012M04 gene (2410012M04Rik)
RIKEN cDNA 2410080P20 gene (2410080P20Rik)
RIKEN cDNA 6230425C22 gene (6230425C22Rik)
RIKEN cDNA C030006K11 gene (C030006K11Rik)
RIKEN cDNA 2810453H10 gene (2810453H10Rik)
RIKEN cDNA 2810026P18 gene (2810026P18Rik)
RIKEN cDNA 2700066J21 gene (2700066J21Rik)
RIKEN cDNA 5730507C05 gene (5730507C05Rik)
RIKEN cDNA 4930553M18 gene (4930553M18Rik)
RIKEN cDNA 2600001M11 gene (2600001M11Rik)
RIKEN cDNA 4833432B22 gene (4833432B22 Rik)
RIKEN cDNA 2810409H07 gene (2810409H07Rik)
RIKEN cDNA 2810470K21 gene (2810470K21Rik)
RIKEN cDNA 2310061O04 gene (2310061O04Rik)
RIKEN cDNA 4930553M18 gene (4930553M18Rik)
RIKEN cDNA 5730436H21 gene (5730436H21Rik)
RIKEN cDNA 2310061I04 gene (2310061I04Rik)
RIKEN cDNA 1110007M04 gene (1110007M04Rik)
RIKEN cDNA 2700079K05 gene (2700079K05Rik)
RIKEN cDNA 2610012O22 gene (2610012O22Rik)
RIKEN cDNA 2410004C24 gene (2410004C24Rik)
RIKEN cDNA 2410008G02 gene (2410008G02Rik)
RIKEN cDNA 2410008J01 gene (2410008J01Rik)
RIKEN cDNA 2410005K20 gene (2410005K20Rik)
RIKEN cDNA 0910001B06 gene (0910001B06Rik)
Target 100910 at MG-U74Av2
Target 98524_f_at MG-U74Av2
Genes downregulated by Myc
Integrin alpha M (Itgam)
aGenes previously described as a Myc targets.
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genes for CACGTG motifs located within 2 kb up- or down-
stream of the start site of transcription (Figure 5A) (24). The
majority of the analyzed genes were indeed found to contain
such E-boxes (Figure 5A). In most of the cases, potential Myc-
binding sequences were located within the first intron or exon1
(Figure 5A). Interestingly though, some of the genes of phy-
siological interest, Gsto1 and Sod2, did not contain CACGTG
sequence within 2 kb upstream of the transcription start site
nor within the gene sequence. However, more distant E-box
elements cannot be excluded. Recent reports suggested
CACGTG motifs, that were located in the first exon or intron
and surrounded by CpG islands (correlating with an open,
preacetylated state of chromatin), to be preferential Myc bind-
ing sites (24). Therefore, taking into account the position of
E-boxes toward a transcription start site, the number of
CACGTG motifs in this region and, the location within
CpG islands, genes presented in Figure 5B were chosen as
candidates for subsequent ChIP analysis.
Formaldehyde-cross linked chromatin was precipitated with
antibodies specific for Myc, acetylated histone H3 or acety-
lated histone H4. Anti-Lyn or anti-PLCg antibodies were used
(irrelevant Ab) as isotype controls. PCR analysis with specific
primers revealed binding of Myc at Ifrd2, Pa2g4, Picalm,
Clpp, Timm10, Lap3, and ATP6v1f sequences (Figure 5B).
PCR bands obtained in this experiment were indeed Myc
specific since 12 h of doxycycline treatment, which completely
abolish Myc expression (Figure 1), results in the disappear-
ance of the signal (Figure 5B). Therefore, according to the
kinetic and chromatin immunoprecipitation data, we con-
cluded that regulation of these genes by Myc is direct. As
expected (36,37), the analyzed Myc binding sequences repre-
sented open chromatin. We were able to precipitate the same
sequences using an antibody specific for acetylated histone H3
both in untreated and doxycycline-treated cells (Figure 5B).
Similar results were obtained using acetylated histone H4 anti-
body (data not shown). This implies that short-term abrogation
of Myc expression, although enough to stop synthesis of
mRNA for the particular gene, did not result in gross altera-
tions in chromatin structure. This is consistent with the pre-
vious report that recruitment of Myc to a target promoter does
not immediately influence the amount of acetylated histones at
the promoter (38).
Myc target genes identified in mouse lymphomas
are also regulated in human lymphomas
The mouse model for conditional Myc-induced lymphoma-
genesis allowed us to identify several new Myc target genes.
The next obvious question was whether Myc might be
involved in regulating the expression of these genes in
Figure 3. RT–PCR confirms the results obtained by Gene Chip analysis. An aliquot of cells that were prepared for microarray analysis was used to isolate total RNA
and subsequently to perform the RT–PCR. Genes commonly upregulated by c-Myc in all analyzed cell lines (Ifrd2, Pa2g4, Picalm, Timm10, Lap3, Sms and Gsto1)
showed a decreased expression upon doxycycline treatment (2 mg/ml for 12 h), while under the same conditions, expression of Itgam, a gene downregulated by Myc,
is increased (A). Expression of the same genes was checked in an additional set of six lymphoma cell lines as biological replicates (B). Examples of up- and
downregulated genes specific for B cell lymphoma (Amd1 and CD2) (C) and T cell lymphoma (Thop1 and CD28) (D) are presented. b-actin was used as a
housekeeping gene.
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Figure 4. Myc target genes follow the kinetics of Myc expression. (A) Myc expression was blocked by treating lymphoma cells with 2mg/ml of doxycycline for 12 h.
Cells were than extensively washed and replated in normal medium. At indicated time points, an aliquot of cells was taken and analyzed for mRNA expression of Myc
regulated genes. Pa2g4, Picalm, Timm10, Lap3, Gsto1 and Sod2 followed kinetic of Myc (expression after 8 h of Myc activation), while Umps and Hells showed later
expression (24 h or later).b-actin was used as a control. Data presenting representative results are shown. (B) Cells were incubated for 12 h in the presence (panel ‘12 h
DOX pretreatment’) or absence (‘control’) of doxycycline. Subsequently, cells were extensively washed, resuspended in RPMI and stained for 5 min with 2 mM of
vital dye CFSE. Cells were replated in cell culture medium and one aliquot of both treated and untreated cells was used for FACS analysis at indicated time points. In
addition, sample of cells continuously that was treated with doxycycline was included. Reduction of CFSE fluorescence indicates proliferation of cells.
Figure 5. Myc binds to the consensus CACGTG sequences in target genes. (A) Mouse genomic DNA sequences for indicated genes, obtained from Celera Discovery
System, were searched for CACGTG motifs located within a distance of 2 kb on either side of transcription start site. Triangles represent consensus binding sites,
whereas full triangles symbolize consensus CACGTG sequences further analyzed by ChIP. Full lines represent exons, dark dashed lines introns and light dashed lines
non-transcribed genomic sequence. (B) Cells treated or not treated with doxycycline, were cross-linked with formaldehyde and the chromatin was
immunoprecipitated using anti-Myc or anti-AC histone H3 antibody. After reverse cross-linking, co-immunoprecipitated DNA was analyzed by PCR using
primers specific for the regions containing CACGTG motifs into indicated Myc target genes. Lyn or PLCg antibodies were used as a negative control
(irrelevant antibody). Representative data obtained with the cell line 5522 B are shown.
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human cells as well. Therefore, we compared the expression of
several genes, which were identified as novel Myc targets in
our mouse system, in human B cells. Primary B cells were
isolated from peripheral blood of healthy donors and com-
pared with primary cases of Burkitt lymphomas. In accordance
with the main feature of Burkitt lymphoma, expression of Myc
in lymphoma samples was significantly higher than in primary
B cells (Figure 6). Importantly, the expression pattern of most
tested Myc target genes correlated with the expression levels
of Myc. The expression levels of Pa2g4, Gsto1, Lap3,
Picalm, Sms, and Timm10 are significantly higher in
Burkitt lymphoma samples when compared with primary B
cells (Figure 6). Moreover, as in the mouse model, Burkitt
lymphomas had lower level of mRNA for Itgam, which was
the only target gene negatively regulated by Myc (Figure 6).
Out of all tested target genes only Sod2 showed the same level
of expression in Burkitt lymphomas and primary B cells (data
not shown), indicating that the Myc-dependence differs
between mouse and human lymphomas for this gene.
DISCUSSION
An analysis of molecular events leading to cancerogenesis is
very important with respect to the attempts to create efficient
antitumor therapies. The role of Myc as a transcription factor
suggests that the initial steps in Myc-induced tumorigenesis
probably involve the transcription of a certain set of genes
critical in the transformation process. Previous reports on
different experimental models revealed that Myc affects
transcription of a large number of genes (23–30). The total
number of these genes analyzed to date is more than 1000,
as listed in the Myc target gene database (www.myccancer-
gene.org). However, it is still an open question, as to which of
the reported target genes triggered by ectopic Myc expression
are indeed essential for tumorigenesis. In addition, not all of
described genes found in this large list have been proven to be
direct Myc targets.
In this study, we identified Myc target genes in a system of
conditional Myc-induced lymphomagenesis. Doxycycline
treatment of cell lines used in our work specifically affects
expression of Myc and Myc-dependent physiological pro-
cesses (31). In our previous work, we observed that over-
expression of Myc that was indirectly controlled by the
mE-driven tTA led to development of both T and B lymphomas
(31). In addition, it was possible to distinguish between two
subgroups of T cell lymphomas according to the number of
copies of chromosome 15 (31). Several recent papers also
reported a link between Myc-induced tumors and an increased
frequency of chromosome 15 trisomy in T cells (39–41). This
study did not aim to identify potentially different expression
patterns in T cell lymphomas that differed in their chromo-
some 15 content. For this more tumor samples need to be
investigated. Nevertheless, we took advantage of this hetero-
geneity in lymphoma in attempts to identify potentially essen-
tial general players in Myc-induced lymphomagenesis and
to reduce the prevalence of genes regulated as a side-effect
of this process.
Microarray analysis revealed that abrogation of Myc
expression by doxycycline affects the expression of a large
number of genes. However, for further analysis we considered
only genes that changed at least 2-fold in all six analyzed cell
lines. Applying these stringent conditions, we reduced the
chance for false positive results and ended up with a list of
88 (61 with known protein function and 27 with non-annotated
sequences) upregulated genes and 1 downregulated gene.
Expression of several genes identified genes in this manner
was also confirmed by RT–PCR analyses of the same cell lines
that were used for Gene Chip as well as an additional set of six
cell lines. Genes were classified into functional groups accord-
ing to their physiological role. The obtained pattern confirms
that Myc regulates genes mainly involved in metabolism
(10 genes), cell cycle control (5 genes), signaling (4 genes),
protein biosynthesis and modification (7 genes).
In addition to 22 genes already reported as a Myc targets,
our analysis revealed that Myc increases the expression of 37
novel genes with known protein function and decreases
expression of only one such gene in all six tested lymphoma
cell lines. We analyzed literature data for all novel Myc targets
and tried to link them with the process of lymphomagenesis.
In all tested lymphomas, doxycycline treatment led to upre-
gulation of Itgam (Mac-1) expression. It is known that Mac-1
is expressed on certain subsets of T and B cells; however, the
precise function of Mac-1 in lymphocyte physiology is not
fully clarified (42,43). Although we could presume that reg-
ulation of an adhesion molecule affects certain aspects of
tumor physiology, i.e. ability to invade different tissues,
Figure 6. Identification of Myc target genes in human Burkitt’s lymphoma.
Total RNA was isolated from primary B cells of three healthy donors and three
individual surgical samples of Burkitt’s lymphoma. RT–PCR was performed to
compare the expression level of Myc and its target genes. b-actin was used as a
housekeeping gene.
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additional studies will be necessary to reveal the role of
downregulation of Itgam expression in Myc-triggered
lymphomagenesis.
We were able to identify a group of genes upregulated by
Myc with roles in mitotic spindle checkpoint and genomic
stability. This group includes Clast3 (CD40 ligand-activated
specific transcript 3), pericentrin 2 and Chek1. Clast3 expres-
sion is controlled in a cell cycle-dependent manner and affects
the regulation of G2-M transition (44). In addition, it interferes
with the mitotic spindle checkpoint, and constitutive over-
expression of Clast3 induces polyploidy and multinucleation
(44). Pericentrin 2 is a calmodulin-binding protein and an
integral component of pericentriolar material (45). Frameshift
mutations of Chek1 were detected in different tumors (46–48).
It was shown that Chek1 is critical for the S and G2 check-
points and, via interactions with Cdc25, regulates the cell
cycle progression (49,50). The well-known ability of Myc
to induce genomic instability (51,52), therefore, could be at
least partially mediated by altered expression of these genes.
It was interesting to find that Myc regulated the expression
of Picalm. This gene fulfilled all criteria for a direct Myc
target. Transcription of Picalm follows the kinetics of Myc
expression and we could detect the binding of Myc protein at
the E-box containing sequence in the first intron of this gene. A
variety of leukemias and lymphomas have been associated
with a translocation that fuses Picalm with the putative tran-
scription factor gene AF10 (53–56). However, the specific role
that overexpressed non-mutated Picalm plays for Myc-
induced lymphomagenesis is not clear. Interestingly, muta-
tions of Picalm appeared to be responsible for the defects
in hematopoiesis and iron metabolism that were observed in
fit-1 mutant mice (57). The significance of iron metabolism in
tumor biology was already reported (58,59). There is also
evidence that Myc activation disturbs iron homeostasis and
it has been reported that iron regulates Myc expression
(60,61). Elevated levels of Picalm could contribute to the
mechanisms involved in the iron-dependent aspects of a
Myc-induced lymphomagenesis.
The potential role of natural polyamines for the processes of
tumorigenesis has been discussed for quite some time
(reviewed in (62)). Indeed, one of the Myc target genes that
was described first was ornithine decarboxylase (ODC), a
critical enzyme in polyamine metabolism (63). We observed
that Myc regulates the expression of another enzyme from this
group, spermine synthase (Sms). Spermine is the most abun-
dant polyamine in human tumors (64) and increases the
resistance of tumor cells to therapy (65). During attempts to
develop an antitumor strategy directed against polyamine pro-
duction, it was observed that ODC inactivation alone did not
alter the spermine concentration (65). It was suggested that
blockade of the single enzyme triggers changes in polyamine
metabolism and transport, which compensates for the defect
(62). In addition to this, we presume that Myc could affect
spermine concentration by direct induction of the spermine
synthase transcription.
Several genes, known to be overexpressed during tumor
development in our study, appeared to be upregulated by
Myc. Gene Chip and ChIP analyses showed that Myc regulates
expression of ATP6V1F, a vacuolar ATPase that is overex-
pressed in human prostate carcinomas (66). Next, we observed
an elevated mRNA level for a lymphoid-specific helicase,
Hells, a molecule shown to be altered in leukemia (67). How-
ever, the expression kinetic for Hells does not follow the Myc
expression directly, and we could not identify E-boxes in the
regulatory region of this gene. Therefore, activation of Hells
by Myc is probably indirect.
A significant number of the upregulated genes have a role in
different metabolic pathways (i.e. Lap3, Clpp, Psat1), mito-
chondrial function (Timm10, Tomm40) or signaling (Ipo4,
Ide). Although, at least some of them (Lap3, Clpp,
Timm10) are direct Myc targets, taking into account the
high proliferative capacity of lymphoma cells, elevated
expression of these genes could represent increased metabolic
requirements of cells rather than being the cause of tumori-
genic transformation.
We also detected upregulation of genes important for stress
response, Stip1, Sod2 and Gsto1. In the case of these genes, we
could not detect consensus Myc binding sites within the 2 kb
sequences surrounding the transcription start. The increased
expression of these genes might be a consequence of the
exposure of cells to oxidative stress (68,69) and not directly
induced by Myc overexpression. Alternatively, Myc binding
sites might be present at more distinct sites relative to the sites
of transcription.
Finally, we found that the results obtained in our mouse
conditional model for lymphomagenesis are relevant for
human neoplasia as well. The same pattern of regulation
for several identified Myc target genes was also observed in
Burkitt lymphoma samples. However, further work is neces-
sary to highlight specific roles of the novel Myc targets and
their importance for Myc-induced tumorigenesis in order to
develop efficient antitumor strategy.
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